PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and treatment-resistant primary membranous nephropathy (TR-pMN). Adolescents with treatment-resistant primary MCD can also participate in this study. The purpose of this study is to find out whether a medicine called BI 764198 helps people with these kidney conditions.
Participants are put into 2 groups randomly, which means by chance. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for 20 weeks. All participants also continue their standard medication for their kidney condition during the study. Participants have twice the chance of being placed in the BI 764198 group than in the placebo group.
Participants are in the study for about 7 months. During this time, they visit the study site 6 times and have 3 phone calls. Doctors regularly test the protein levels in participants' urine by collecting urine samples. They also check kidney function by taking blood samples. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date23 Mar 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07220083

/ RecruitingPhase 3

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.
Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.
Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.
Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date16 Feb 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07308652

/ CompletedPhase 1

The Effect of Multiple Doses of Itraconazole on the Single-dose Pharmacokinetics of BI 764198 Following Oral Administration in Healthy Male Trial Participants (an Open-label, Non-randomised, Two-period, Fixed-sequence Design Study)

The purpose of this study is to find out whether a medicine called itraconazole changes the amount of another medicine called BI 764198 in the blood. Some people may take more than 1 medicine at a time. Therefore, it is important to understand how medicines influence each other. This study will help us learn more about how BI 764198 works.

Start Date09 Feb 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Apecotrep

100 Translational Medicine associated with Apecotrep

100 Patents (Medical) associated with Apecotrep

Literatures (Medical) associated with Apecotrep

01 Feb 2026·LANCET

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198

Article

Author: Kretzler, Matthias ; Prasad, Srinivasa ; Cross, Nicholas ; Gesualdo, Loreto ; Licarião Rocha, Fabia T ; Retlich, Silke ; Trachtman, Howard ; Kaufeld, Jessica ; Ye, Zhiming ; Meijers, Björn ; Lobmeyer, Maximilian T ; Chen, Qinkai ; Soleymanlou, Nima ; Derebail, Vimal K ; Ng, Monica Suet Ying ; Ji, Bo ; Workeneh, Biruh

BACKGROUND:

In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198.

METHODS:

This multicentre phase 2, double-blind, placebo-controlled, randomised controlled trial assessed BI 764198 (20 mg, 40 mg, or 80 mg once daily) versus placebo over 12 weeks in participants aged 18-75 years with biopsy-confirmed primary FSGS (based on the absence of clinical evidence of secondary cause) or with a disease-causing TRPC6 variant. The study took place in 31 sites in ten countries, and random allocation was performed centrally in blocks in a 1:1:1:1 ratio and was stratified according to use of corticosteroids. Participants were receiving stable conservative and immunosuppressive therapy, with screening urine protein-creatinine ratio (UPCR) at 1·0 g/g or greater and estimated glomerular filtration rate at 30 mL/min per 1·73 m² or greater. The primary endpoint was the proportion of participants with proteinuria response (≥25% UPCR reduction from baseline) at week 12. Other key outcomes were safety and tolerability. The study was registered with ClinicalTrials.gov on Jan 27, 2022 (NCT05213624) and is complete as of Jan 3, 2025.

FINDINGS:

From March 10, 2022, to Sept 3, 2024, 139 participants were screened and 67 were randomly assigned to receive placebo or BI 764198 at doses of 20 mg, 40 mg, or 80 mg (five participants were randomly assigned in error and were not treated). 62 participants received treatment, two of whom had missing baseline or post-baseline UPCR measurements and were not included in the full analysis set. Overall, 37 participants (60%) were male and 25 participants (40%) were female; the mean age was 40·7 years (SD 12·6); and the majority of the trial cohort were White (39 [63%] of 62). Proteinuria responses were observed in eight (44%) of 18, two (14%) of 14, and six (43%) of 14 participants receiving BI 764198 20 mg, 40 mg, and 80 mg, respectively (16 [35%] of 46 for all BI 764198 doses) versus one (7%) of 14 receiving placebo; corresponding odds ratios (ORs) versus placebo were OR 10·0 (95% CI 1·6-118·1), 1·5 (0·2-19·5), and 6·0 (0·9-73·6) for the three doses of BI 764198, and 4·9 (1·0-48·8) for all doses combined. BI 764198 was well tolerated with no meaningful differences in adverse event frequencies across treatment arms; treatment-emergent adverse events were reported by 44 (71%) of 62 participants, with similar frequencies of adverse events observed in the placebo group (ten [71%] of 14) and BI 764198 groups (34 [71%] of 48).

INTERPRETATION:

BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials over longer treatment durations, enabling meaningful subgroup analyses, are planned to evaluate the safety and efficacy of BI 764198 treatment in FSGS and other conditions affected by podocytopathy.

FUNDING:

Boehringer Ingelheim.

04 May 2025·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment

Article

Author: Atef Halabi ; Silke Retlich ; Armin Schultz ; Friedeborg Seitz ; Nima Soleymanlou ; Hauke S. Wülfrath ; Katrien Lemmens ; Wansuk Choi ; Maximilian T. Lobmeyer

BACKGROUND:

BI 764198 could reduce podocyte injury in focal segmental glomerulosclerosis (FSGS).

RESEARCH DESIGN AND METHODS:

Four Phase 1 BI 764198 trials: single rising dose (SRD) and multiple rising dose (MRD)/drug-drug interaction trials in healthy volunteers; relative bioavailability (rBA) study (food and formulations effects on pharmacokinetics; PK); and kidney impairment (KI) PK study.

RESULTS:

SRD trial: 4/54 BI 764198-treated participants (7.4%) had ≥ 1 investigator-defined drug-related adverse event (DRAE): headache (n = 3; 5.6%); diarrhea (n = 1; 16.7%). BI 764198 PK was approximately linear. MRD trial: DRAEs occurred in 5/32 (15.6%) participants receiving BI 764198 and 1/8 (12.5%) receiving placebo. Once-daily BI 764198 80 mg (10 days) did not alter midazolam PK. All BI 764198 formulations tested had similar rBA; food did not affect PK. KI study: geometric mean ratios for area under the plasma concentration-time curve were 147.8% and 177.7% for participants with moderate and severe KI, respectively (vs. without). Limitations include typically small Phase 1 sample sizes and open-label design for the rBA and KI trials.

CONCLUSIONS:

BI 764198 was well tolerated and could be taken with/without food; evaluation in FSGS is ongoing.

CLINICAL TRIAL REGISTRATION:

The trials are registered at www.clinicaltrials.gov with codes NCT03854552; NCT04102462; NCT04656288; NCT04176536.

01 Dec 2023·Kidney international reports

TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design

Article

Author: Desmond, Hailey E ; Kretzler, Matthias ; Choi, Wansuk ; Soleymanlou, Nima ; Manuel, Raymond C ; Trachtman, Howard

Focal segmental glomerulosclerosis (FSGS), a leading glomerular cause of kidney failure, is a histological pattern characterized by podocyte injury and depletion.1 FSGS is found in 20–30% of adults with nephrotic syndrome and up to 20% of patients receiving dialysis.2,S1 FSGS can be broadly categorized into four causative classifications: primary (idiopathic), secondary (adaptive), familial (genetic), and of unknown cause.1,3,S2 Depending on patient selection and region, genetic variants have been reported in up to 14% of individuals with adult-onset FSGS.

News (Medical) associated with Apecotrep

28 Jan 2026

·endpoints.news

Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

Boehringer Ingelheim’s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than two higher levels. Nonetheless, Boehringer has just begun a Phase 3 study. Data from the Phase 2 trial showed that the drug, called apecotrep, cut levels of protein in the urine of patients with a form of kidney damage known as primary focal segmental glomerulosclerosis (FSGS). The trial tested three doses of apecotrep. Its primary endpoint was proteinuria response, defined as a reduction of at least 25% in the urine protein creatinine ratio, which is a measure of kidney function. According to data from the study published in the Lancet , responses were seen in 44% of patients given 20 mg once-daily doses of apecotrep. In the 40 mg and 80 mg cohorts, 14% and 43% of subjects responded, respectively. The placebo group’s response rate was 7%. Patients given the lowest 20 mg dose had a placebo-adjusted reduction in proteinuria of 40% after three months of treatment, the company said Wednesday. The Lancet data show this was the dose with the strongest response on this measure, despite being the lowest. Patients given 40 mg and 80 mg of Boehringer’s drug had placebo-adjusted proteinuria reductions of just 5% and 23%, respectively. The Lancet paper authors suggested that the lack of a dose response “indicates that an efficacy plateau is likely being reached with the 20 mg dose.” They added that the 40 mg group had the fewest evaluable participants — just 10 — and the largest number of dropouts, “increasing the variability of observations in this group versus other groups.” According to the Lancet data, the drug was well tolerated, with no meaningful differences in side-effect rates between the treatment and placebo arms. Treatment-emergent adverse events were reported by 71% of subjects in both the apecotrep and placebo arms. Patients with FSGS have scar tissue and loss of podocytes, cells that line the glomerular filtration units of the kidney. This causes protein to leak into the urine rather than being absorbed by the body. FSGS can be secondary to an infection or diseases, including diabetes and lupus, but in primary FSGS, the cause is unknown. No approved disease-modifying therapy for FSGS currently exists. Boehringer’s drug, also known as BI 764198, is a potential first-in-class TRPC6 inhibitor. TRPC6 overactivity could be a cause of podocyte loss and kidney function decline. The drug is now in a placebo-controlled Phase 3 study, which is signing up adults and adolescents with primary FSGS. This will have the same primary endpoint, but will be assessed after two years of treatment. The record on the federal trials database does not list what dose or doses will be studied. Boehringer said it would also start a Phase 2 trial of other proteinuric kidney diseases, including secondary FSGS and Alport syndrome, in the first quarter of this year.

Phase 3Clinical ResultPhase 2

28 Jan 2026

·firstwordpharma.com

Hoping for clear-cut win, Boehringer starts pivotal study of FSGS drug

Boehringer Ingelheim has kicked off a Phase III study of the experimental TRPC6 inhibitor apecotrep (BI 764198) in people with primary focal segmental glomerulosclerosis (FSGS), despite the once-daily, oral therapy showing mixed results in an earlier trial. The company disclosed the start of the late-stage study on Wednesday, alongside supporting data published in The Lancet.Results from a Phase II trial showed that across all doses of apecotrep, proteinuria responses occurred in 35% of patients, compared to 7.1% for placebo. A treatment response was defined as a ≥25% reduction in urine protein-creatinine ratio (UPCR) after 12 weeks.The study randomised 62 participants aged 18-75 years with biopsy-confirmed primary FSGS or with a disease-causing TRPC6 variant to receive one of three doses of apecotrep or placebo.While the 20-mg dose of apecotrep was associated with a proteinuria response rate of 44%, the rate for the 40-mg dose was only 14%, with it rising for the 80-mg dose to 43%. Results also showed that in the 20-mg dose group, there was a 40% reduction in UPCR versus placebo.Boehringer said that apecotrep was well tolerated in the study, with rates of adverse events being 71% for both the drug and placebo.Despite the mixed signal for apecotrep, lead investigator Howard Trachtman said "these clinically relevant findings reinforce the importance of further investigation of its potential as a first-in-class targeted treatment for primary FSGS, where the unmet need remains high."Along with FSGS, Boehringer is investigating apecotrep in other proteinuric kidney diseases, with a Phase II trial set to start in the first quarter. The experimental drug is designed to protect podocytes from the excessive calcium entering cells — which is thought to be caused by overactivation of the TRPC6 protein — thus slowing down disease progression by decreasing proteinuria.

Phase 2Clinical ResultPhase 3

28 Jan 2026

·www.biospace.com

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental glomerulosclerosis (FSGS). Primary FSGS is a rare kidney condition in which injury and loss of podocytes, the cells responsible for the kidney’s filtration system, lead to proteinuria and kidney failure over time. Phase II trial results, published in The Lancet, demonstrated a 40% reduction in proteinuria with apecotrep (20 mg dose group) compared to placebo after 12 weeks of treatment. The Phase III trial is open for recruiting adults and adolescents with primary FSGS. An additional Phase II trial in other proteinuric kidney diseases will start in the first quarter of this year. Boehringer Ingelheim today announced results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor for people with primary focal segmental glomerulosclerosis (FSGS). Apecotrep reduced proteinuria, a key indicator associated with kidney damage, by 40% in the 20 mg dose group compared to placebo. 1 The results were published in The Lancet and presented at the 2025 American Society of Nephrology (ASN)’s Kidney Week. The Phase III trial ( NCT07220083 ) is open for recruiting adults and adolescents with primary FSGS. An additional Phase II trial ( NCT07355296 ) evaluating the safety and efficacy of apecotrep in other proteinuric kidney diseases will start in the first quarter of this year. Apecotrep demonstrates Boehringer’s commitment to addressing high unmet medical needs across a broad spectrum of kidney diseases. This includes primary kidney conditions where no approved disease-modifying therapies currently exist. “The results underscore Boehringer’s scientific leadership in kidney health and deep commitment to people living with cardiovascular, renal, and metabolic diseases, including rare kidney conditions like FSGS,” said Paola Casarosa, Head of Innovation Unit, Board of Managing Directors, Boehringer Ingelheim. “With the Phase III trial now underway, we are advancing apecotrep driven by the potential to deliver the first disease-modifying treatment for primary FSGS and redefine the standard of care for patients.” Primary FSGS is a rare, progressive kidney disease which can end in kidney failure. 2,3,4 Despite its severity and burden for patients, there are currently no approved targeted therapies. 5,6,7 There remains a significant unmet need for a targeted therapy that addresses the root cause of the disease. “Primary FSGS is a serious glomerular disease and an important cause of kidney failure in both children and adults. By targeting the underlying mechanism of primary FSGS, apecotrep reduced proteinuria by 40% compared to placebo, with a favorable tolerability pro adults,” said Howard Trachtman, Lead Investigator, University of Michigan. “These clinically relevant findings reinforce the importance of further investigation of its potential as a first-in-class targeted treatment for primary FSGS, where the unmet need remains high.” In primary FSGS, the protein Transient Receptor Potential Channel 6 (TRPC6) is hypothesized to be overactivated on podocytes, cells responsible for the kidney’s filtration system. 8 This allows excessive calcium to enter the cells, causing progressive podocyte injury and loss, and ultimately, proteinuria and kidney disease progression. Apecotrep intends to protect podocytes and slow down disease progression by decreasing proteinuria. 9 Highlighting its potential as a new treatment option for primary FSGS, apecotrep was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China and Orphan Drug Designations by the European Medicines Agency (EMA) and the Japanese Ministry for Health, Labour and Welfare (MHLW). About apecotrep (BI 764198) and the Phase II trial Apecotrep is an investigational, potential first-in-class, oral, once daily, non-immunosuppressive TRPC6 inhibitor that is being developed as a potential treatment for people living with primary FSGS. 9 Its mechanism of action intends to counter the overactivation of TRPC6, a protein channel essential for the structure and function of podocytes, which are specialized cells responsible for the kidney’s filtration system. 9 The compound was discovered and developed by Boehringer Ingelheim, and is part of its Cardiovascular-Renal-Metabolic portfolio. In the Phase II trial, a response to treatment defined as greater than or equal to 25% reduction in urine protein-creatinine ratio (UPCR) was observed in 35% of participants receiving apecotrep across all dose groups after 12 weeks, compared to 1 out of 14 (7.1%) in the placebo arm. The greatest proportion of patients responding to apecotrep were in the 20mg dose (44.4%). Furthermore, a 40% (p=0.0024) reduction in UPCR compared to placebo was observed with 20 mg dose. 1 Finally, apecotrep was generally well-tolerated. About FSGS Focal segmental glomerulosclerosis (FSGS) is a type of podocytopathy in which podocyte injury and loss result in excess protein in the urine (proteinuria). Approximately, 50% of people with primary FSGS progress to end-stage kidney disease (ESKD) within 5-10 years. 10 FSGS is a leading cause of nephrotic syndrome in adults and is estimated to affect up to 0.8 per 100,000 population globally. 7 The condition is associated with scarring in the kidney’s filtering units called glomeruli and causes swelling of legs and other parts of the body, foamy urine, fatigue, weight gain, high blood pressure, and cholesterol increase. 11 Primary FSGS means that the disease occurs without a known cause, while secondary FSGS is caused by another known cause such as infection, diabetes or obesity. 11 Additionally, genetic FSGS results from mutations in podocyte or glomerular basement membrane proteins or specific susceptibility genes such as TRPC6 . 12,13 About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at . References 1 Trachtman H, et al. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomized, placebo-controlled, phase 2 trial of BI 764198. Lancet. 2026;S0140-6736(25)02255-X. 2 Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clinical Journal of the American Society of Nephrology. 2017;12:502–517. 3 Munis MA, et al. Incidence and proportion of primary focal segmental glomerulosclerosis (FSGS) among a racially and ethnically diverse adult patient population between 2010 and 2021. Clinical Journal of the American Society of Nephrology. 2025;20(2):229-238. 4 Ossareh S, et al. Kidney outcome in primary focal segmental glomerulosclerosis (FSGS) by using a predictive model. Iranian Journal of Kidney Diseases. 2021;15(6):408-418. 5 Buttgereit F, et al. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;365:801–803. 6 Trachtman H. Emerging drugs for treatment of focal segmental glomerulosclerosis. Expert Opinion on Emerging Drugs. 2020;25(3):367-375. 7 McGrogan A, et al. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrology Dialysis Transplantation. 2011;26(2):414-30. 8 Kim EY, et al. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors. Molecular Basis of Disease. 2017;1863(9):2342-2354. 9 Trachtman H, et al. TRPC6 inhibitor BI 764198 in focal segmental glomerulosclerosis: Phase 2 study design. Kidney International Reports. 2023;;8(12):2822-2825. 10 Bensink ME, et al. Kidney failure attributed to focal segmental glomerulosclerosis: a USRDS retrospective cohort study of epidemiology, treatment modalities, and economic burden. Kidney Medicine. 2023;6(2):100760. 11 Mayo Clinic. Focal segmental glomerulosclerosis (FSGS). Available at: . Accessed January 2026. 12 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100:S1-S276. 13 Winn MP et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005;308(5729):1801-4.

Phase 2Clinical ResultBreakthrough TherapyOrphan DrugPhase 3

100 Deals associated with Apecotrep

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulosclerosis, Focal Segmental	Phase 3	United States	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	China	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Japan	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Argentina	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Australia	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Belgium	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Brazil	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Bulgaria	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Canada	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Croatia	Boehringer Ingelheim GmbH	16 Feb 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05863130 (CTgov)	Phase 1	-	24	BI 764198 (Cohort 1: Classical hADME)	dtywpzdogp(pdsqnlopha) = wtxjlgiwyj rcbrfrlrbz (wmpssrwoqx, 6.23) View more	-	03 Jun 2026
				BI 764198 (Cohort 2: Microtracer hADME)	dtywpzdogp(pdsqnlopha) = crwdohkfaf rcbrfrlrbz (wmpssrwoqx, 6.04) View more
NCT05213624 (Pubmed \| Lancet)	Phase 2	Glomerulosclerosis, Focal Segmental	62	BI 764198 20 mg	zgobacbkqs(ksfisgqqjn) = ydbflgyhjy ifnnrsvztv (kbumsyxwyy ) View more	Positive	01 Feb 2026
				BI 764198 40 mg	zgobacbkqs(ksfisgqqjn) = rzvdjmavxw ifnnrsvztv (kbumsyxwyy ) View more
NCT05213624 (CTgov)	Phase 2	Glomerulosclerosis, Focal Segmental \| Chronic Kidney Diseases	67	BI 764198 (BI 764198 20 mg)	kcjqssuqun = dmxsgzbfal aorytgdbgf (xjwjynxhxm, cynspkvarl - utqyvangse) View more	-	12 Jan 2026
				BI 764198 (BI 764198 40 mg)	kcjqssuqun = bgrkhkcanw aorytgdbgf (xjwjynxhxm, hjtfzhatuc - ytbklimfxy) View more
NCT05213624 (ASN2025)	Phase 2	Glomerulosclerosis, Focal Segmental	60	BI 764198	vybmjydvte(quwpaazpip) = isojhgqvav uoggcjjanf (rxrsadzspp )	Positive	08 Nov 2025
				BI 764198	vybmjydvte(quwpaazpip) = ldnycixqgm uoggcjjanf (rxrsadzspp )
NCT04102462 \| NCT03854552 \| NCT04176536 \| NCT04656288 (Phase 1 trials of BI 764198, Pubmed \| Expert Opin Investig Drugs)	Phase 1	Renal Insufficiency	54	BI 764198	xiiljpqoxb(iyozmecrzb) = 1 participant (16.7%) experienced diarrhea tehburtkpf (xkaroccpvs ) View more	Positive	04 May 2025
				Placebo
NCT04665700 (Pubmed \| Expert Opin Investig Drugs)	Phase 1	TRPC6	44	BI 764,198 20 mg	oxtjstdpmi(pzkvqvupcw) = dpshiwcikd guwynodqia (ipbsbknkyd ) View more	-	04 May 2025
				Placebo	oxtjstdpmi(pzkvqvupcw) = lydtqqnics guwynodqia (ipbsbknkyd ) View more
NCT04604184 (Pubmed)	Phase 2	COVID-19	-	BI 764198	sppbkxkuez(nyktfamtiq): days = 3.41 (95% CI, 0.49 - 6.34) View more	Negative	06 Apr 2023
				Placebo
NCT04604184 (CTgov)	Phase 2	COVID-19 \| Respiratory Distress Syndrome, Acute	133	BI 764198 (BI 764198 Treatment Group)	txyphpvirk = gkxhteecnf kizwzniuoc (peyyidwjis, uqvljfogcx - fvmtstwtin) View more	-	11 Apr 2022
				Placebo (Placebo)	txyphpvirk = xhgmajrkxl kizwzniuoc (peyyidwjis, wsxnecfcmj - tjqdbvtxiy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis